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Abstract
Background: Plasminogen activator inhibitor −2 (PAI-2) is an important molecular that plays a crucial role in vascular
homeostasis and constitutes a critical response mechanism to cardiovascular injury, such as atherosclerosis, coronary
artery disease (CAD).
Methods: The aim of the current study was to explore the association between the variants in PAI-2 gene and CAD and
its prognoses. The three variants (rs8093048, rs9946657, rs9320032) of the PAI-2 gene were detected in 407 patients with
CAD and 518 control subjects. All patients with CAD underwent one-year follow-up for major adverse cardiac events
(MACE).
Results: The frequencies of the TT genotype and T allele of rs8093048 was significantly higher in CAD patients
than that in control subjects (7.6 % vs.3.5 %, P = 0.003, 28.1 % vs.21.7 %, P < 0.001, respectively). Multifactor logistic
regression analysis showed that the TT genotype of rs8093048 was a risk factor for CAD (OR = 1.455, 95 % CI: 1.069-1.980,
P = 0.017). In addition, the follow-up data showed that CAD patients with rs8093048 TT genotype had significantly
higher rate of refractory angina and MACE than those with CC or CT genotype (P = 0.032, P = 0.009, respectively).
Cox regression analysis showed that rs8093048 TT genotype was the risk factor for the MACE (Hazard ratio = 5.672, 95 %
CI = 1.992-16.152, P = 0.001).
Conclusion: We firstly found that the variant of PAI-2 gene was associated with CAD and recurrent coronary event risk in
Chinese Han population, in Xinjiang.
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Background
The plasminogen activator (PA) system plays a key role
in vascular homeostasis and constitutes a critical re-
sponse mechanism to cardiovascular injury, such as ath-
erosclerosis, coronary artery disease (CAD), myocardial
infarction (MI) and restenosis [1]. The central compo-
nents of the PA system are the proteolytic activators,
urokinase-plasminogen activator (u-PA) and tissue-type
plasminogen activator (t-PA), plasminogen (plg) and its
degradation product, plasminogen activator inhibitor-1
(PAI-1) and plasminogen activator inhibitor −2 (PAI-2) [2].
PAI-2 is widely expressed in various cells, such as mono-
cytes and macrophages, eosinophils, keratinocytes, micro-
glia, and endothelial and epithelial cells, and is intensely
upregulated in inflammation, infection, pregnancy, and
other pathophysiological conditions [3–5]. It is predomin-
antly expressed as a 47 kDa non-glycosylated intra cellular
form located in the cytoplasm, but it can also be found as a
glycosylated 60–70 kDa protein located in the extracellular
surface [6, 7]. PAI-2 has been proposed to play a role in
different processes, including protection of the retinoblast-
oma protein from degradation, regulation of keratinocyte
and monocyte proliferation, and differentiation, priming
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interferon α/β responses, inhibition of annexin-1 cleavage,
interleukin 1β processing, promotion of adipose tissue de-
velopment, and the inhibition of apoptosis [8].
CAD is a complex and multifactorial disorder involving
the interaction of genetic factors and environmental fac-
tors. Despite significant improvement in clinical manage-
ment of the CAD, it is still reported as the most common
cause of adult deaths worldwide [9, 10]. While lifestyle
modification has reduced the mortality rate, the candidate
gene approach has provided new insights for exploring
diagnostic and therapeutic approaches. PAI-2 gene consists
of 8 exons spanning 16.18 kb on the long arm of chromo-
some 18 [11]. Nur Buyru et al. investigated 45 myocardial
infarction patients and 20 control subjects, they found that
the variant at the 413 position (AA genotype) of PAI-2
gene was associated with an increased risk of MI [12].
James P. Corsetti et al. found that the polymorphism of
rs6095 in PAI-2 gene was the continued significant risk of
recurrent coronary event among 166 patients with high
high-density lipoprotein-cholesterol (HDL-C) and C-
reactive protein levels [13]. Moreover, Zhao et al. geno-
typed 57 patients with CAD and 62 controls, it indicated
that PAI-2 gene Ser/Cys413 15588 G/C polymorphism was
associated with CAD and the C allele was a risk factor for
CAD [14]. In the current study, we recruited a larger sam-
ple (407 CAD patients and 518 control subjects) to investi-
gate the association between PAI-2 gene and CAD in
Chinese Han population. And we built a prospective co-
hort study of the CAD patients to analyze the major ad-
verse cardiac events (MACE) among different genotypes of
PAI-2 gene for a mean period of one-year follow-up.
Methods
Ethics statement
Written informed consents were obtained from all the
participants. The study was approved by the Ethics
Committee of the First Affiliated Hospital of Xinjiang
Medical University and conducted according to the
principles outlined in the Declaration of Helsinki.
Subjects
All CAD patients and control subjects were recruited at
the First Affiliated Hospital of Xinjiang Medical University
from 2010 to 2013. 407 CAD patients and 518control sub-
jects were randomly recruited in this study. All of the
participants were genetically-unrelated. All of the CAD
patients were defined by angiographic means (main cor-
onary artery stenosis of >50 %). For the control group, we
selected healthy participants matched for sex, and age.
Control subjects were selected from the Cardiovascular
Risk Survey (CRS) [15, 16]. Briefly, the CRS is a pro-
spective, observational cohort study designed to investi-
gate the prevalence, incidence, and risk factors for
cardiovascular disease in the Han, Uygur, and Kazakh
populations in Xinjiang of China. The control partici-
pants were defined as with no coronary vessel stenosis
or clinical and electrocardiographic evidence of MI or
CAD. All patients with kidney disease, malignancy,
connective tissue disease, schizophrenia, or chronic in-
flammatory disease were excluded.
Laboratory examination and definition of cardiovascular
risk factors
The plasma concentration of blood triglyceride (TG), total
cholesterol (TC), HDL-C, and low-density lipoprotein-
cholesterol (LDL-C), were measured using standard
methods in the Clinical Laboratory Department of First Af-
filiated Hospital, Xinjiang Medical University. Hypertension
was defined as history of hypertension and/or an average
systolic blood pressure (SBP) ≥ 140 mmHg and/or an aver-
age diastolic blood pressure (DBP) ≥90 mmHg on at least 2
separate occasions according to the medical examination
and history. Diabetes was defined as history or presence of
diabetes and/or a fasting plasma glucose level >7.0 mmol/L
(126 mg/dl) on 2 separate occasions, or a random glucose
value of >11.1 mmol/L (200 mg/dl) on ≥1 occasion. Body
mass index (BMI) was calculated from standardized mea-
surements of height and weight. Persons reporting regular
tobacco use in the previous 6 months were considered as
current smokers.
DNA Extraction
Blood samples were collected from all participants after
fasting for 12 h. Genome DNA was extracted from per-
ipheral vein blood leukocytes using a whole blood gen-
ome extraction kit (Boiteke Corporation, Beijing, China).
SNP selection
In this study, we screened the data on the National
Center for Biotechnology Information SNP database
(www.ncbi.nlm.nih.gov/SNP) for the SNPs of PAI-2
gene. There are 141 SNPs listed in the SNP database.
We used the minor allele frequency (MAF) ≥0.1 and
linkage disequilibrium patterns with r2 ≥ 0.5 as a cut off
by the Haploview 4.2 software. We achieved 7 tag SNPs
listed in the HapMap phrase II database. SNPs with
relatively high MAF have been shown to be useful as
genetic markers in genetic association studies. Based on
the screening for markers to be used in our genetic as-
sociation research, we selected 3 SNPs (rs9946657,
rs8093048, rs9320032) which located in a haplotype re-
gion. rs8093048 located in the 3’untranslated region
(UTR) of the flotillin-2 gene, rs9320032 located in the
intron, and rs9946657 located in the 5’ UTR.
Genotyping
We used TaqMan® SNP genotyping assays (Applied
Biosystems, Foster City, CA). The primers and probes
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used in the TaqMan® SNP Genotyping Assays were chosen
based on information available at the ABI website. The
polymerase chain reaction (PCR) amplification was per-
formed in 96 well plates adding 2.5 μL of TaqMan
Universal Master Mix (40×), 0.15 μL probes and 1.85 μL
ddH2O in a 6 μL final reaction volume containing 1.5 μL
DNA. Separate negative control group and positive con-
trol group in each plate. The PCR amplification was per-
formed using the 7900HT sequence detection system and
the amplified condition was as follows: 95 °C for 5 min;
40 cycles of 95 °C for 15 s; and 60 °C for 1 min. All 96 well
plates were read on Sequence Detection Systems (SDS)
automation controller software v2.3 (ABI).
Clinical follow-up and judgment of endpoint events
Follow-up examination was performed on one year after
discharge. Follow-up information was collected through
out-patient review, telephone call, and readmission. Record
the general information of the patients and the end point
events. The primary end point used was MACE, defined as
death, refractory angina, MI, target vessel revascularization
(TVR), and cerebrovascular events [transient ischemic at-
tack (TIA), stroke and reversible ischemic injury].
Statistical analysis
All analyses were performed using the computer software
Statistical Package for Social Sciences-SPSS for Windows
(version 17.0). Hardy-Weinberg equilibrium was assessed
by using chi-square analysis. Continuous data were
expressed as mean ± standard deviation (SD) and the dif-
ferences between the CAD patients and the control partic-
ipants were assessed by independent samples t test.
Categorical data and distribution of genotypes and alleles
were shown as percentages (%) and the differences be-
tween the two groups were assessed by chi-square test.
Logistic regression analysis was performed to assess the
contribution of the major risk factor to CAD and the value
was shown as odds ratio (OR) and its 95 % confidence
interval (CI). In addition, the COX regressive analysis was
used to assess the clinical prognosis among different geno-
type of Flotillin-2 gene. P < 0.05 was considered to indicate
a statistically significant difference.
Results
Characteristics of participants
A total of 925 individuals (407 patients with CAD and 518
healthy controls) were participated in this study. There
were no differences in age between CAD patients and con-
trol subjects, suggesting that the study was an age‑matched
case‑control study. The concentration of HDL-C was sig-
nificantly lower in patients with CAD than that in control
subjects (P = 0.026). However, the percentage of individuals
with EH, DM and smoking were significantly higher in
CAD patients than that in control subjects (P = 0.013, P <
0.001, and P < 0.001, respectively). No significant differ-
ences in BMI, pulse and concentration of TC, TG, LDL-C
were observed between the two groups (Table 1).
Distribution of the flotillin-2 genotype
The genotype distribution of the three SNPs in PAI-2
gene did not show any significant difference from
Hardy-Weinberg equilibrium (all P > 0.05, the data did
not show). The frequency of genotype and allele of PAI-2
gene in CAD patients and controls were shown in Table 2.
There were significant differences in genotypic and allelic
distribution of PAI-2 gene between CAD patients and
controls. The PAI-2 gene rs8093048 TT genotype and T
allele distribution was significantly higher in CAD patients
than that in control subjects (7.6 % versus 3.5 %, P =
0.003, 28.1 % versus 21.7 %, P < 0.001, respectively). For
rs9946657 and rs9320032, we did not found any signifi-
cant difference in the genotypic and allelic distribution of
PAI-2 gene between CAD patients and controls.
Logistic regression analysis of CAD risk factors
Multifactor logistic regression analyzed the contribu-
tion of the major risk factor to CAD. It showed that
rs8093048 T allele carriers (TT + CT), DM, and smok-
ing were the risk factors for CAD. Following adjust-
ments for DM, EH, TC, LDL-C, HDL-C, and smoking,
the subjects with T allele of rs8093048 (TT + CT) had a
significantly higher risk of CAD (OR = 1.455, 95 % CI:
1.069-1.980, P = 0.017) (Table 3).
Table 1 Characteristics of study participants in Chinese Han
population
CAD patients Control subjects P value
Number of subjects 407 518
Age(years) 62.36(10.62) 62.40(9.45) 0.951
Men, n (%) 290(71.3) 348(67.2) 0.184
BMI (kg/m2) 25.70(3.38) 26.06(4.10) 0.153
Pulse (beats/min) 73.04(10.42) 72.72(10.32) 0.641
TC (mmol/L) 4.44(0.97) 4.33(1.03) 0.165
TG (mmol/L) 1.84(1.23) 1.91(1.62) 0.470
LDL (mmol/L) 2.46(0.91) 2.44(0.84) 0.824
HDL (mmol/L) 1.16(0.49) 1.24(0.58) 0.026*
EH,n (%) 219(53.8) 236(45.6) 0.013*
DM, n (%) 107(26.3) 61(11.8) <0.001*
Smoking, n (%) 233(57.2) 184(35.5) <0.001*
Continuous variables are expressed as mean ± s.d. Categorical variables are
expressed as percentages. CAD coronary artery disease, BMI body mass index,
total TC cholesterol, TG triglycerides, LDL-C Low-density lipoprotein-cholesterol,
HDL-C high-density lipoprotein-cholesterol, EH essential hypertension, DM
diabetes mellitus. The P value of the continuous variables was calculated by
the independent samples t test. The P value of the categorical variables was
calculated by Chi square test. *P < 0.05
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Result of clinical follow-up
One year follow-up data were available in 397 of the
original 407 CAD patients (Table 4). The missing rate
was 2.46 %. Overall, 27 MACE occurred during the
one-year study (6.8 %). There were 4 patients died
(1.0 %), 6 patients occurred refractory angina (1.5 %), 5
patients had MI (1.25 %), 4 patients had target vessel
revascularization (1.0 %), 8 patients occurred cerebro-
vascular events (2.0 %). The rate of refractory angina
and MACE were significantly different among the three
different genotype of rs8093048 (Fig. 1). Cox regression
analysis showed that rs8093048 TT genotype was the risk
factor for the MACE (Hazard ratio = 5.672, 95 % CI =
1.992-16.152, P = 0.001) (Table 5).
Discussion
In the current study, we observed that the variation in the
PAI-2 gene was associated with CAD and its prognosis in
Chinese Han subjects. Individuals with TT genotype of
rs8093048 had significantly higher risk of CAD and worse
prognosis than that with CC or CT genotype. The rate of
refractory angina was significantly higher in CAD patients
with TT genotype than that with CC or CT genotype. The
results demonstrated that the polymorphism of PAI-2
gene may be as a marker of CAD and its prognosis.
PAI-2 is an important molecular of the serpin superfam-
ily. It’s an efficient inhibitor of t-PA and u-PA and an im-
portant regulatory element in fibrinolysis. To maintain
normal blood flow, fibrinolysis and hemostasis should
exist in a precise balance in which fibrinolysis restricts ex-
cessive blood clots and hemostasis prevents excessive
blood loss. Because serine proteases in both fibrinolysis
and hemostasis are the key enzymes, both processes are
primarily controlled by serine protease inhibitors (serpins,
such as PAI-1, PAI-2, α2-AP) [17–20]. Genetic deficiency,
excessive expression, or dysfunction of one or more of
these serpins may cause pathological bleeding or throm-
bosis. In normal physiological conditions, PAI-2 is only
detectable in plasma during pregnancy and probably has a
role in maintaining the placenta or in embryonic develop-
ment [21, 22]. It’s worth noting that there was strong cor-
relation between elevated tPA and PAI-2 levels in gingival
crevicular fluid during inflammation, and the balance be-
tween them remains constant during the inflammatory
process [23, 24]. Moreover, the overexpression of PAI-2
could inhibit the proliferation and migration and pro-
motes the apoptosis of human pulmonary arterial smooth
muscle cells [25]. Intracellular PAI-2 affects cellular prolif-
eration and differentiation, alters gene expression, and in-
hibits apoptosis [26, 27].
But so far, the reason and mechanism of PAI-2 and CAD
are unclear. We firstly indicated that PAI-2 gene may be a
candidate gene of CAD in Chinese Han population. It was
consistent with the previous researches. Cerrahpasa et al.
found that AA genotype of the PAI-2 gene was found to be
more frequent among those subjects with MI [12]. James
et al. demonstrated independent association of the PAI-2
polymorphism reference allele with recurrent cardiovascu-
lar disease risk [13]. Zhao et al. reported that PAI-2 gene
Ser/Cys413 polymorphism is associated with CAD, the C
Table 2 Genotype and allele distributions of PAI-2 gene in CAD
patients and controls
Variants Genotyping/allele CAD patients Control subjects P value
rs9946657 GG 114(28.0 %) 155(29.9 %)
GT 211(51.8 %) 273(52.7 %)
TT 82(20.2 %) 90(17.4 %) 0.532
T 375(46.1 %) 453(43.7 %)
G 439(53.9) 583(56.3 %) 0.314
rs8093048 CC 209(51.4 %) 311(60.0 %)
CT 167(41.0 %) 189(36.5 %)
TT 31(7.6 %) 18(3.5 %) 0.003
C 585(71.9 %) 811(78.3 %)
T 229(28.1 %) 225(21.7 %) <0.001*
rs9320032 CC 13(3.2 %) 18(3.5 %)
CT 119(29.2 %) 152(29.3 %)
TT 275(67.6 %) 348(67.2 %) 0.828
C 145(17.8 %) 188(18.1 %)
T 669(82.2 %) 848(81.9 %) 0.853
Table 3 Multiple logistic regression analysis for CAD patients
and control subjects in Chinese Han population
Risk factors Odd ratios 95 % CI P value
rs8093048 (TT + CT v.s. CC) 1.455 1.069-1.980 0.017*
DM 1.724 1.174-2.531 0.005*
Hypertension 1.263 0.925-1.725 0.142
TC 1.165 0.951-1.429 0.141
LDL 0.916 0.726-1.155 0.457
HDL 0.805 0.60-1.079 0.146
Smoking 3.506 2.564-4.794 <0.001*
CAD coronary artery disease, DM diabetes mellitus, LDL-C Low-density
lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol. *P < 0.05
Table 4 The occurrence of adverse events in patients with CAD
during one year follow-up
End point CC(204) CT(163) TT(30) P value
Death, n (%) 2(1.0) 1(0.6) 1(3.3) 0.39
refractory angina, n (%) 1(0.5) 3(1.8) 2(6.7) 0.032*
MI, n (%) 2(1.0) 2(1.2) 1(3.3) 0.558
TVR, n (%) 1(0.5) 2(1.2) 1(3.3) 0.324
cerebrovascular events, n (%) 4(2.0) 3(1.8) 1(3.3) 0.864
MACE, n (%) 10(4.9) 11(6.7) 6(20.0) 0.009*
MI myocardial infarction, TVR target vessel revascularization. *P < 0.05
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allele is a risk factor for CAD and the G allele is a pro-
tective factor for CAD [14]. However, the Physician’s
Health Study and ECTIM did not support an associ-
ation between polymorphism PAI-2 and acute coronary
syndrome [17]. The contradiction may lie in the differ-
ences in gene expression between different ethnic
population and the small >sample in the two studies. In
the other hand, Palafox-Sa´nchez found that the func-
tional Ser(413)/Ser(413) PAI-2 polymorphism was asso-
ciated with susceptibility and damage index score in
systemic lupus erythematosus [28]. Moreover, the poly-
morphism of PAI-2 gene was also associated with anti-
phospholipid syndrome [29]. These disease states all
relate to disorders in hemostasis, highlighting the role
of PAI-2 gene in this system.
There were certain limitations in our study. Firstly,
we only detected the association between the 3 SNPs
in PAI-2 gene with the CAD. As we know, SNPs are
the most abundant form of genetic variations and have
a great potential for mapping genes underlying com-
plex genetic traits. But their effects were micro-effect.
Much more studies of the other SNPs are needed to
investigate the mechanism of CAD and PAI-2 gene.
Secondly, the level of plasma concentration of PAI-2
was not measured in our study because of their low
concentrations. However, there was an advantage in
the present study what the sample size was relatively
large. It was better to indicate the association between
PAI-2 gene and CAD.
Conclusions
In conclusion, we are more convinced that the variant in
PAI-2 gene may be associated with the susceptibility to
CAD and its prognosis in Chinese Han population. Indi-
viduals with rs8093048 TT and CT genotype had signifi-
cantly higher risk of CAD and worse prognosis than that
with CC genotype. The rate of refractory angina was sig-
nificantly higher in CAD patients with TT genotype than
that with CC or CT genotype.
Fig. 1 The survival among different genotype of rs8093048 in Chinese Han CAD patients
Table 5 COX regression analysis in Chinese Han CAD patients
OR SE P value Hazard ratio(95 % CI)
BMI 0.04 0.061 0.514 1.041(0.923-1.174)
TG 0.069 0.174 0.694 1.071(0.761-1.507)
TC −0.054 0.257 0.833 0.947(0.573-1.567)
LDL-C 0.328 0.252 0.193 1.388(0.847-2.274)
HDL-C 0.123 0.384 0.749 1.131(0.533-2.399)
Hypertension 0.06 0.413 0.884 1.062(0.473-2.387)
DM 0.647 0.415 0.119 1.909(0.847-4.304)
Smoking 0.274 0.442 0.536 1.315(0.552-3.128)
rs8093048 genotype
CC - - - -
CT 0.38 0.445 0.393 1.463(0.611-3.501)
TT 1.736 0.534 0.001* 5.672(1.992-16.152)
BMI body mass index, TC cholesterol, TG triglycerides, LDL-C Low-density
lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, DM diabetes
mellitus. *P < 0.05
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